Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14830999 | 0.77 | NCF1 (0.37) | KMT2A | |
| SCHEMBL22337376 | 0.73 | GAA (0.42) | KMT2A | |
| SCHEMBL69979 | 0.72 | CRHBP (0.37) | CRHBPCRHR2KMT2ASIRT2 | |
| SCHEMBL21672130 | 0.68 | — | — | |
| SCHEMBL31317257 | 0.68 | NQO1 (0.40) | — | |
| SCHEMBL25206895 | 0.68 | CRHBP (0.38) | CRHBPCRHR2KMT2ASIRT2 | |
| SCHEMBL2787712 | 0.67 | RAB9A (0.45) | KMT2A | |
| SCHEMBL1128351 | 0.67 | KDM4E (0.44) | — | |
| SCHEMBL561873 | 0.65 | PRMT5 (0.30) | — | |
| SCHEMBL31628072 | 0.65 | ALDH1A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739390-A1 | 2-(1H-INDOL-4-YL)METHYL)2H-INDAZOLE DERIVATIVES AS FACTOR B INHIBITORS | Sitala Bio Ltd (GB) | 2026-05-13 | — | — | EP | disclosed |
| US-20260125375-A1 | SUBSTITUTED 1H-PYRAZOLO-PYRIDINE AND -PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| WO-2025128781-A1 | AZAINDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-4562009-A1 | NOVEL COMPOUNDS | AC Immune SA (CH) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025111547-A1 | 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF | RGENTA THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025008451-A1 | 2-(1H-INDOL-4-YL)METHYL)2H-INDAZOLE DERIVATIVES AS FACTOR B INHIBITORS | SITALA BIO LTD (GB) | 2025-01-09 | — | — | WO | disclosed |
| CN-114585609-B | 2H-indazole derivatives and their use in the treatment of diseases | 比奥根MA公司 | 2024-07-30 | — | — | CN | disclosed |
| WO-2024074977-A1 | SUBSTITUTED 1 H-PYRAZOLO-PYRIDINE AND-PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-9296740-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| EP-1906965-B1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2015-05-06 | — | — | EP | disclosed |
| US-20130338157-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8383630-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110098308-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-7777035-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090252779-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| US-7524845-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20070010524-A1 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | CRHBP 3102/4885CRHR2 1474/4885KMT2A 289/4885 |
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CRHBP 397/4885CRHR2 287/4885KMT2A 3304/4885 |
| US-20070010524-A1 | Azaindazole compounds and methods of use | CCR1, CCR3, CCR4 | CRHBP 397/4885CRHR2 287/4885KMT2A 3304/4885 |
| US-20260125375-A1 | SUBSTITUTED 1H-PYRAZOLO-PYRIDINE AND -PYRIMIDINE COMPOUNDS | CCR1, CCR6, CCRL2 | CRHBP 3738/4885CRHR2 595/4885KMT2A 3684/4885 |
| US-20090252779-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CRHBP 397/4885CRHR2 287/4885KMT2A 3304/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | CRHBP 3240/4885CRHR2 243/4885KMT2A 605/4885 |
| US-20110098308-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CRHBP 397/4885CRHR2 287/4885KMT2A 3304/4885 |
| US-20130338157-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | CRHBP 397/4885CRHR2 287/4885KMT2A 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.